Psychedelic medicine continues to show real promise as treatment for mental illnesses. There has been an overwhelming amount of positive results in patients with Alzheimer’s, PTSD, depression anxiety, and addiction. In this article we will dive into how psychedelics help treat psychiatric illnesses and the future of the industry.

Over the past decade there has been an explosion in psychedelic research. It’s surprising that scientific research on psychedelics has surged despite the fact that psychedelics are classified as a schedule 1 drug. Scientists have been working in a bit of gray area, but governments around the world are changing their position and classification of psychedelics.

Studies show that even a single dose of a psychedelics can have long lasting impacts. A recent study found a single dose of psilocybin associated with increased mindfulness three months later. Another study by the University College London found that a single dose of Ketamine can help with alcohol addiction. Research into the amount and number of doses still needs to be studied, but it goes to show how powerful the impacts are of a single serving.

The emergence of publicly traded psychedelic companies is another huge milestone for the industry. Being a publicly traded company adds credibility to the psychedelic field and shows that the general public is interested in investing in the emerging industry. As the industry heats up, companies are also patenting and trademarking all types of IP to gear up for a change is legislation. 

As time progresses psychedelics have moved from a purely recreational substance to a medicine that can heal complicated psychiatric illnesses. It’s no longer a matter of if psychedelics will be legal medicine… but a matter of when.